Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
area is swollen and sore and pink; area is swollen and sore and pink; area is swollen and sore and pink; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site swelling in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 16-FEB-2025, the patient received Shingrix. In FEB-2025, an unknown time after receiving Shingrix, the patient experienced injection site swelling (Verbatim: area is swollen and sore and pink), injection site pain (Verbatim: area is swollen and sore and pink) and injection site discoloration (Verbatim: area is swollen and sore and pink). The outcome of the injection site swelling, injection site pain and injection site discoloration were not reported. It was unknown if the reporter considered the injection site swelling, injection site pain and injection site discoloration to be related to Shingrix. It was unknown if the company considered the injection site swelling, injection site pain and injection site discoloration to be related to Shingrix. Additional Information: GSK Receipt Date: 17-FEB-2025 This case was reported by a patient via interactive digital media. The patient received Shingrix vaccine and the area was swollen, sore and pink. The reporter was this normal.